Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Orbital Neoplasms | 1 | 2019 | 11 | 0.600 |
Why?
|
| Vision Disorders | 1 | 2019 | 38 | 0.590 |
Why?
|
| Hepatitis C | 1 | 2019 | 41 | 0.580 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 133 | 0.540 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 167 | 0.520 |
Why?
|
| Peritoneal Diseases | 1 | 2013 | 1 | 0.420 |
Why?
|
| Gravidity | 1 | 2013 | 6 | 0.420 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2013 | 6 | 0.420 |
Why?
|
| Decidua | 1 | 2013 | 4 | 0.420 |
Why?
|
| Thyroid Gland | 1 | 2013 | 32 | 0.410 |
Why?
|
| Cesarean Section | 1 | 2013 | 55 | 0.400 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 39 | 0.400 |
Why?
|
| Carcinoma | 1 | 2013 | 74 | 0.390 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 80 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 337 | 0.340 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2019 | 24 | 0.250 |
Why?
|
| Biomarkers, Tumor | 3 | 2013 | 409 | 0.230 |
Why?
|
| Lighting | 1 | 2024 | 9 | 0.220 |
Why?
|
| Microscopy | 1 | 2024 | 38 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 253 | 0.190 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 10 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 147 | 0.160 |
Why?
|
| Middle Aged | 4 | 2022 | 7310 | 0.140 |
Why?
|
| Visual Acuity | 1 | 2019 | 119 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 84 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 465 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 478 | 0.120 |
Why?
|
| Humans | 7 | 2024 | 28581 | 0.110 |
Why?
|
| Pregnancy, Twin | 1 | 2013 | 6 | 0.100 |
Why?
|
| Carcinoma, Medullary | 1 | 2013 | 1 | 0.100 |
Why?
|
| Thyroidectomy | 1 | 2013 | 6 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 3 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2013 | 15 | 0.100 |
Why?
|
| Biopsy | 1 | 2013 | 207 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2013 | 241 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 378 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 480 | 0.090 |
Why?
|
| Male | 3 | 2019 | 13771 | 0.090 |
Why?
|
| Female | 4 | 2022 | 15471 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 29 | 0.080 |
Why?
|
| Pregnancy | 1 | 2013 | 1219 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2013 | 2612 | 0.080 |
Why?
|
| Risk Factors | 1 | 2013 | 2111 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 546 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 681 | 0.060 |
Why?
|
| Color | 1 | 2024 | 23 | 0.050 |
Why?
|
| Fourier Analysis | 1 | 2024 | 31 | 0.050 |
Why?
|
| Adult | 2 | 2013 | 7922 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 2 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2022 | 34 | 0.050 |
Why?
|
| Triazines | 2 | 2013 | 11 | 0.050 |
Why?
|
| Benzoquinones | 2 | 2013 | 26 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 2 | 2013 | 26 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 75 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 89 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 72 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 104 | 0.040 |
Why?
|
| Pyrazoles | 2 | 2013 | 70 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 1338 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 8 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 12 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 9 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 33 | 0.020 |
Why?
|
| ras Proteins | 1 | 2013 | 43 | 0.020 |
Why?
|
| Indazoles | 1 | 2013 | 18 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 63 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 41 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 61 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 31 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2013 | 100 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 61 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 140 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 164 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 416 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 24 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 270 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 864 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 515 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2045 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2804 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 5525 | 0.010 |
Why?
|